

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jul 2026

The effect of prescription versus not prescription of the prophylactic antibiotic on clinical outcomes in newborn with transient tachypnea: a triple blind randomized clinical trial

Protocol summary

Summary

Objectives: To assess the effect of prescription versus not prescription of the prophylactic antibiotic on clinical outcomes in newborn with transient tachypnea. **Design:** a triple blind randomized clinical trial. **Setting and conduct:** The eligible newborns with transient tachypnea who will hospitalized in the Fatemeh Hospital during the study period will be enrolled into the trial. **Inclusion criteria:** Neonate with gestational age of 34 to 41 weeks; respiratory distress for at least 4 hours. **Exclusion criteria:** prenatal or perinatal infection; congenital anomalies; disposal of meconium during delivery; Apgar score of 7 or lower; pneumonia; indication of mechanical ventilation; signs of primary septicemia; need for additional oxygen with pressure more than 40%. **Intervention group:** Routine care plus ampicillin 25 mg/kg 3 times a day for 72 hours and amikacin 10 mg/kg 2 times a day for 72 hours **Control group:** Just routine care. **Primary outcome:** (a) assessing the incidence of pneumonia on the first, second, and third days after intervention through physical examination; (b) assessing the signs of septicemia on the first, second, and third days after intervention through physical examination; (c) assessing the incidence of death on the first, second, and third day after intervention through physical examination **Secondary outcome:** (a) assessing duration of hospitalization based on medical record at discharge; (b) assessing blood culture on the first, second, and third days after intervention through laboratory test; (c) assessing adverse effect of medications such as renal failure on the first, second, and third days after intervention through laboratory test. **Randomization:** The patients will be randomly assigned to intervention and control groups using block randomization. **Blinding:** newborns will be unaware of the type of intervention. The physician who will examine the patients will not be aware of the intervention. The analyzer will be unaware

of the type of interventions. Therefore, the trial will be run as triple blind.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201609049014N114**

Registration date: **2016-09-08, 1395/06/18**

Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2016-09-08, 1395/06/18

Registrant information

Name

Jalal Poorolajal

Name of organization / entity

Department of Epidemiology & Biostatistics Hamadan University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 81 1838 0090

Email address

poorolajal@umsha.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice-chancellor for Research the Technology, Hamadan University of Medical Sciences

Expected recruitment start date

2016-08-22, 1395/06/01

Expected recruitment end date

2017-09-22, 1396/06/31

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The effect of prescription versus not prescription of the prophylactic antibiotic on clinical outcomes in newborn with transient tachypnea: a triple blind randomized clinical trial

Public title

The effect of prescription versus not prescription of the prophylactic antibiotic on clinical outcomes in newborn with transient tachypnea

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: Neonate with gestational age of 34 to 41 weeks; respiratory distress for at least 4 hours.
Exclusion criteria: prenatal or perinatal infection; congenital anomalies; disposal of meconium during delivery; Apgar score of 7 or lower; pneumonia; indication of mechanical ventilation; signs of primary septicemia; need for additional oxygen with pressure more than 40%.

Age

From **1 day** old to **7 days** old

Gender

Both

Phase

2

Groups that have been masked

No information

Sample size

Target sample size: **100**

Randomization (investigator's opinion)

Randomized

Randomization description**Blinding (investigator's opinion)**

Triple blinded

Blinding description**Placebo**

Not used

Assignment

Parallel

Other design features

Randomization: The patients will be randomly assigned to intervention and control groups using block randomization. Blinding: newborns will be unaware of the type of intervention. The physician who will examine the patients will not be aware of the intervention. The analyzer will be unaware of the type of interventions. Therefore, the trial will be run as triple blind.

Secondary Ids

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics Committee of Hamadan University of Medical Sciences

Street address

Vice-chancellor for Research the Technology,
Hamadan University of Medical Sciences, Shahid Fahmideh Ave

City

Hamadan

Postal code

6517838695

Approval date

2016-08-06, 1395/05/16

Ethics committee reference number

IR.UMSHA.REC.1395.224

Health conditions studied**1****Description of health condition studied**

Transient tachypnea

ICD-10 code

P22.1

ICD-10 code description

Transient tachypnoea of newborn

Primary outcomes**1****Description**

assessing the incidence of pneumonia

Timepoint

on the first, second, and third days after intervention

Method of measurement

through physical examination

2**Description**

assessing the signs of septicemia

Timepoint

on the first, second, and third days after intervention

Method of measurement

through physical examination

3**Description**

assessing the incidence of death

Timepoint

on the first, second, and third day after intervention

Method of measurement

through physical examination

Secondary outcomes

1

Description

assessing duration of hospitalization

Timepoint

based on medical record

Method of measurement

at discharge

2

Description

assessing blood culture

Timepoint

on the first, second, and third days after intervention

Method of measurement

through laboratory test

3

Description

assessing adverse effect of medications such as renal failure

Timepoint

on the first, second, and third days after intervention

Method of measurement

through laboratory test

Intervention groups

1

Description

Just routine care

Category

Treatment - Other

2

Description

Routine care plus ampicillin 25 mg/kg 3 times a day for 72 hours and amikacin 10 mg/kg 2 times a day for 72 hours

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center**Name of recruitment center**

Fatemieh Hospital

Full name of responsible person

Dr Leila Bahadorbeigi

Street address

Fatemieh Hospital, Pasdaran Ave.

City

Hamadan

Sponsors / Funding sources

1

Sponsor**Name of organization / entity**

Vice-chancellor for Research the Technology,
Hamadan University of Medical Sciences

Full name of responsible person

Dr Saeid Bashirian

Street address

Hamadan University of Medical Sciences, Shahid
Fahmideh Ave

City

Hamadan

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Vice-chancellor for Research the Technology, Hamadan
University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

empty

Person responsible for general inquiries

Contact**Name of organization / entity**

Fatemieh Hospital

Full name of responsible person

Dr Leila Bahadorbeigi

Position

Pediatric Resident

Other areas of specialty/work**Street address**

Fatemieh Hospital, Pasdaran Ave.

City

Hamadan

Postal code**Phone**

+98 81 3828 3939

Fax**Email**

bahar_liela@yahoo.com

Web page address

Person responsible for scientific inquiries

Contact**Name of organization / entity**

Fatemieh Hospital
Full name of responsible person
Dr Mohammad Kazem Sabzei
Position
Pediatrics
Other areas of specialty/work
Street address
Fatemieh Hospital, Pasdaran Ave
City
Hamadan
Postal code
Phone
+98 81 3828 3939
Fax
Email
mk_sabzehei@yahoo.com
Web page address

Person responsible for updating data

Contact
Name of organization / entity
Department of Epidemiology
Full name of responsible person
Dr Jalal Poorolajal
Position
Associate Professor
Other areas of specialty/work
Street address

School of Public Health, Hamadan University of
Medical Sciences, Shahid Fahmideh Ave
City
Hamadan
Postal code
6517838695
Phone
+98 81 3838 0090
Fax
Email
poorolajal@umsha.ac.ir
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty
Study Protocol
empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty